We reach more than 65,000 registered users in Dec!!

Glycoscience fuels a new breed of cancer immunotherapy

Start-ups like Palleon and NextCure look to broaden the benefits of immuno-oncology with drugs that target a protein family called Siglecs and their glycan ligands

Leave a comment

Search Similar Posts

    No tags found for this post